Apremilast for Extensive and Treatment-Resistant Alopecia Areata: A Retrospective Analysis of Five Patients

April 2020 in “ European Journal of Dermatology ”

Benedikt Weber, Sonja Radaković, Adrian Tanew

Studysummary This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on stm.cairn.info →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

research Efficacy of the Phosphodiesterase-4 Inhibitor, Apremilast, in a Patient with Severe Alopecia Areata

10 citations , August 2019 in “European Journal of Dermatology”

This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.

$Apremilast Is Efficacious in Refractory Alopecia Areata$

research Apremilast Is Efficacious in Refractory Alopecia Areata

9 citations , May 2019 in “Journal of dermatological treatment”

This article reviews characteristics and mental health impacts of alopecia areata but provides no new clinical findings; future research is encouraged.

A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata

42 citations , November 2018 in “Archives of dermatological research”

Apremilast was not effective in treating moderate-to-severe alopecia areata.

research Lack of Efficacy of Apremilast in 9 Patients with Severe Alopecia Areata

23 citations , September 2017 in “Journal of the American Academy of Dermatology”

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

77 citations , June 2017 in “Advances in Therapy”

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

research A Novel Therapeutic Paradigm for Patients with Extensive Alopecia Areata

30 citations , May 2016 in “Expert Opinion on Biological Therapy”

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism

68 citations , November 2015 in “The Journal of Allergy and Clinical Immunology”

In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.

research The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo

52 citations , December 2014 in “Journal of Dermatological Science”

Apremilast may help treat hair loss in alopecia areata.

research The Effect of Oral Cyclosporine in the Treatment of Severe Alopecia Areata

33 citations , October 2013 in “Cutaneous and ocular toxicology”

This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.

research Systemic Treatment for Alopecia Areata

16 citations , May 2011 in “Dermatologic therapy”

This article reviews side effects and relapse rates of various systemic treatments for severe alopecia areata, reporting no new clinical findings.

research Alopecia Areata: Clinical Presentation, Diagnosis, and Unusual Cases

109 citations , May 2011 in “Dermatologic Therapy”

This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.

research Alopecia Areata Update

391 citations , January 2010 in “Journal of The American Academy of Dermatology”

This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.

research A Comparison of the Efficacy, Relapse Rate, and Side Effects Among Three Modalities of Systemic Corticosteroid Therapy for Alopecia Areata

97 citations , January 2006 in “Dermatology”

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.